Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of lamivudine in combination with standard of care
chemoimmunotherapy in treating patients with extensive stage small cell lung cancer. Even
though small cell lung cancer is initially highly responsive to first-line chemotherapy
treatment, treatment resistance inevitably emerges; treatment resistance is when tumor cells
stop responding to a drug treatment that they had previously responded to. Lamivudine is an
oral antiviral a drug that may be able to reduce the ability of tumors to develop drug
resistance. Chemotherapy drugs, such as carboplatin and etoposide, work in different ways to
stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as
atezolizumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Giving lamivudine together with the usual standard
of care chemoimmunotherapy may help prevent the growth and spread of the tumor cells to other
parts of the body.